Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of New RotaTeq Formulation in Infants
NCT01600092Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2013
- Primary completion
- Mar 2014
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of rotavirus vaccine, live, oral, pentavalent in rotavirus gastroenteritis, sponsored by Merck & Co.. Started Apr 2013; status: completed.
02
Drugs
rotavirus vaccine, live, oral, pentavalent
03
Conditions
rotavirus gastroenteritis
Beyond the preview
Go deeper on NCT01600092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01600092.